Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?

Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3Z activatory domain connected to 4-1BB costimulatory domain. Liso-cel, unlike the other two approved products—axicabtagene ciloleucel and tisagenlecleucel—is manufactured sepa...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Mohamed A. Kharfan-Dabaja, Farah Yassine, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant Murthy
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wolters Kluwer Medknow Publications 2022-10-01
סדרה:	Hematology/Oncology and Stem Cell Therapy
נושאים:	cd19 chimeric antigen receptor t cell diffuse large b cell non-hodgkin lymphoma lisocabtagene maraleucel
גישה מקוונת:	https://journals.lww.com/10.1016/j.hemonc.2021.09.004
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!